ATE325876T1 - Isolierte peptide, die an hla-c moleküle binden und deren verwendung - Google Patents

Isolierte peptide, die an hla-c moleküle binden und deren verwendung

Info

Publication number
ATE325876T1
ATE325876T1 AT01973479T AT01973479T ATE325876T1 AT E325876 T1 ATE325876 T1 AT E325876T1 AT 01973479 T AT01973479 T AT 01973479T AT 01973479 T AT01973479 T AT 01973479T AT E325876 T1 ATE325876 T1 AT E325876T1
Authority
AT
Austria
Prior art keywords
hla
molecules
bind
isolated peptides
peptides
Prior art date
Application number
AT01973479T
Other languages
English (en)
Inventor
Sacha Ludwig Gnjatic
Lloyd J Old
Yasuhiro Nagata
Elke Jager
Yao-Tseng Chen
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cornell Res Foundation Inc filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE325876T1 publication Critical patent/ATE325876T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01973479T 2000-09-26 2001-09-24 Isolierte peptide, die an hla-c moleküle binden und deren verwendung ATE325876T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/670,456 US6506875B1 (en) 2000-09-26 2000-09-26 Isolated peptides which bind to HLA-C molecules and uses thereof

Publications (1)

Publication Number Publication Date
ATE325876T1 true ATE325876T1 (de) 2006-06-15

Family

ID=24690468

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973479T ATE325876T1 (de) 2000-09-26 2001-09-24 Isolierte peptide, die an hla-c moleküle binden und deren verwendung

Country Status (10)

Country Link
US (2) US6506875B1 (de)
EP (1) EP1320609B1 (de)
JP (1) JP4174570B2 (de)
CN (1) CN1253572C (de)
AT (1) ATE325876T1 (de)
AU (2) AU9305101A (de)
CA (1) CA2423481C (de)
DE (1) DE60119552T2 (de)
HK (1) HK1060594A1 (de)
WO (1) WO2002026778A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CN105085616A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种氨基酸序列及其应用
CN105085615A (zh) * 2014-05-23 2015-11-25 上海市普陀区中心医院 一种多肽序列及其应用
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
KR20180128915A (ko) 2016-02-26 2018-12-04 오클랜드 유니서비시즈 리미티드 아미노산 및 펩티드 접합체 및 접합 방법
CA3132252A1 (en) * 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
ATE356206T1 (de) * 1997-10-08 2007-03-15 Us Gov Health & Human Serv Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
CA2317492A1 (en) * 1998-01-23 1999-07-29 Ludwig Institute For Cancer Research Isolated, polypeptides which bind to hla-a29 molecules, nucleic acid, the molecules encoding these, and uses thereof
US6710172B1 (en) * 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2001062917A1 (en) * 2000-02-22 2001-08-30 Ludwig Institute For Cancer Research Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof

Also Published As

Publication number Publication date
US20030050451A1 (en) 2003-03-13
CA2423481A1 (en) 2002-04-04
AU2001293051B2 (en) 2007-04-26
CN1253572C (zh) 2006-04-26
DE60119552D1 (de) 2006-06-14
WO2002026778A3 (en) 2003-02-13
AU9305101A (en) 2002-04-08
EP1320609B1 (de) 2006-05-10
JP4174570B2 (ja) 2008-11-05
EP1320609A2 (de) 2003-06-25
US7009035B2 (en) 2006-03-07
JP2004524271A (ja) 2004-08-12
HK1060594A1 (en) 2004-08-13
US6506875B1 (en) 2003-01-14
CN1476480A (zh) 2004-02-18
DE60119552T2 (de) 2007-04-19
WO2002026778A2 (en) 2002-04-04
CA2423481C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
DE69636450D1 (de) PEPTIDE UND PEPTIDOMIMETIKA MIT STRUKTURELLER ÄHNLICHKEIT MIT p53 UND DIE DIE p53-FUNKTION AKTIVIEREN
DE60032486D1 (de) Prion protein peptide und deren verwendung
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ES2075196T3 (es) Metodo para el uso y la sintesis de peptidos.
MY109957A (en) Improved antibodies to plasmodium falciparum
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
EP1708745A4 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
EP0739350A4 (de) Fas-antigenbindender ligand
IL123189A0 (en) Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
ATE362941T1 (de) Identifikation, reinigung und verwendungen von leczymen und karbohydratliganden
ATE325876T1 (de) Isolierte peptide, die an hla-c moleküle binden und deren verwendung
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
DE60025704D1 (de) Das goodpasture-antigen bindende protein
WO2003068800A3 (en) Isolated peptides which bind to hla molecules and uses thereof
ATE405582T1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
ATE283281T1 (de) T-zell epitope des raygraspollen-allergens
TR200200631T2 (tr) Alfa-2/Delta geni
Siklodi et al. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells
WO1992016623A3 (en) Receptors for bombesin-like peptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320609

Country of ref document: EP